Evidence map›Paper›PMID 18794525›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2008

Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans.

Anton Y Peleg, Emmanouil Tampakakis, Beth Burgwyn Fuchs, George M Eliopoulos, Robert C Moellering, Eleftherios Mylonakis

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Microbiology spectrum · 2026
    Article
  5. Review
  6. Observational
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anton Y PelegDivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA
Emmanouil Tampakakis
Beth Burgwyn Fuchs
George M Eliopoulos
Robert C Moellering
Eleftherios Mylonakis

Funding

A C.elegans high-throughput assay for the identification of new antifungal agentsR01AI075286 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MYLONAKIS, ELEFTHERIOS · 2008 to 2010
$1.3M
C.elegans as a model system forC.neoformans pathogenesisK08AI063084 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MYLONAKIS, ELEFTHERIOS · 2005 to 2007
$378k
NIAID NIH HHS K08 AI063084NIAID NIH HHS K08 AI63084NIAID NIH HHS R01 AI075286
6 · The paper itself

Abstract

Prokaryote-eukaryote interactions are ubiquitous and have important medical and environmental significance. Despite this, a paucity of data exists on the mechanisms and pathogenic consequences of bacterial-fungal encounters within a living host. We used the nematode Caenorhabditis elegans as a substitute host to study the interactions between two ecologically related and clinically troublesome pathogens, the prokaryote, Acinetobacter baumannii, and the eukaryote, Candida albicans. After co-infecting C. elegans with these organisms, we observed that A. baumannii inhibits filamentation, a key virulence determinant of C. albicans. This antagonistic, cross-kingdom interaction led to attenuated virulence of C. albicans, as determined by improved nematode survival when infected with both pathogens. In vitro coinfection assays in planktonic and biofilm environments supported the inhibitory effects of A. baumannii toward C. albicans, further showing a predilection of A. baumannii for C. albicans filaments. Interestingly, we demonstrate a likely evolutionary defense by C. albicans against A. baumannii, whereby C. albicans inhibits A. baumannii growth once a quorum develops. This counteroffensive is at least partly mediated by the C. albicans quorum-sensing molecule farnesol. We used the C. elegans-A. baumannii-C. albicans coinfection model to screen an A. baumannii mutant library, leading to the identification of several mutants attenuated in their inhibitory activity toward C. albicans. These findings present an extension to the current paradigm of studying monomicrobial pathogenesis in C. elegans and by use of genetic manipulation, provides a whole-animal model system to investigate the complex dynamics of a polymicrobial infection.

Indexed as

Acinetobacter baumanniiAnimalsBacterial ProteinsBiofilmsCaenorhabditis elegansCandida albicansFarnesolGenetic TestingMutationVirulenceBacterial ProteinsFarnesol

Identifiers

PMID18794525
PMCPMC2567192

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.